Intermittent time-restricted feeding recapitulates the physiological benefits of daily time-restricted feeding in male mice with chronic metabolic disease Authors: Andre Sarmento-Cabral, Marta G Novelle, Luz Marina Sánchez-Mendoza, Natalia Herman-Sanchez, Samanta Lozano de la Haba, Marta Rodriguez-Vazquez, Pablo Iturbe, Eduardo Chicano-Gálvez, Francisco Javier Cubero, Raul M Luque, Jose Cordoba-Chacon, Juan L Lopez-Canovas, Jose M Villalba, Manuel D Gahete, Alberto Diaz-Ruiz Published: 2026 ABSTRACT AbstractTime-restricted feeding (TRF) is proposed as a relevant strategy to counteract obesity and metabolic disorders; however, the therapeutic efficacy of more pragmatic intermittent TRF (iTRF) regimens remains undefined. Herein, daily and intermittent TRF significantly improved whole-body physiology, promoted key hallmarks of energy restriction, and induced coordinated transcriptional and lipidomic remodeling in male mice with chronic metabolic dysfunction previously established by prolonged high-fat, high-cholesterol, high-fructose feeding. These effects were summarized using three composite scores capturing physiological/metabolic, energy restriction, and lipidic responses, which consistently separated daily and intermittent TRF regimens from ad libitum-fed mice. Lipidomic profiling identified a subset of hepatic lipids associated with systemic health, pointing to lipid remodeling, particularly at the endoplasmic reticulum, as a potential feature of the TRF response. Notably, TRF failed to histologically improve hepatic steatosis, ballooning, or inflammation, and its overall benefits were clearly inferior to dietary normalization to standard chow diet. Altogether, these data (i) demonstrate that intermittent TRF recapitulates the beneficial effects in advanced metabolic disease, (ii) provides translational support for flexible TRF strategies, and (iii) highlights the need to integrate TRF with additional therapeutic strategies.Keywords: Time-restricted feeding, Whole-body physiology, Metabolic homeostasis, Lipidomics Introduction Noncommunicable diseases (NCDs) account for approximately 75% of non-pandemic-related death worldwide, remaining the leading cause of global morbidity and mortality [[1], [2], [3]]. Overweight and obesity, elevated blood pressure (including hypertension), high blood glucose levels, and abnormal blood lipids (including high cholesterol) represent metabolic risk factors increasing the risk of developing NCDs [1,4]. In 2030, one in two adults will have obesity [1]. In parallel, 25% of the global population is already affected by metabolic dysfunction-associated steatotic liver disease (MASLD), recognized as the predominant cause of liver-related morbidity and mortality [[5], [6], [7], [8]]. Both conditions, obesity and MASLD, constitute chronic, multi-systemic disorders that compromise specific organs beyond adipose tissue and the liver, notably increasing the risk of several co-morbidities such as cardiovascular disease, chronic kidney disease and type 2 diabetes mellitus (T2DM) [9]. The prevalence of MASLD is markedly higher in individuals with obesity and/or T2DM, reaching 70–75% and 80%, respectively [10], in line with the fact that NCDs are interconnected and driven by similar metabolic risk factors. In addition, given that (i) NCDs are complex with no “one-size-fits-all” drug available [11], and (ii) patient adherence to prescribed treatments for NCDs remains suboptimal [12], integrative multidisciplinary approaches in which personalized medication is combined with nutritional-based lifestyle interventions are fundamental to cooperatively reverse interconnected NCDs or to prevent their pathological progression [13,14]. Therapeutic diets based on energy restriction represent sustainable treatments against obesity and MASLD [[15], [16], [17], [18]]. The metabolic response promoted by energy restriction is influenced by fundamental components of the eating architecture, which include timing and distribution of daily calories, meal frequency, and/or the length of inter-meal fasts [19,20]. Beyond the classical continuous caloric restriction, several intermittent energy restriction-based interventions have emerged, which include time-restricted feeding, alternate days of energy restriction, periodic fasting and/or fasting-mimicking diets, the latter designed to induce a physiological state of fasting without complete food deprivation [21]. Shared health-related benefits by energy restriction interventions have been consistently observed in both preclinical and clinical research, and include weight loss, improvement of insulin sensitivity, reduction of chronic inflammation, prevention of cardiovascular and neurological diseases, as well as anti-cancer protection [17,[22], [23], [24]]. Mechanistically, energy restriction triggers the activation of AMP-activated protein kinase, inhibition of the mechanistic target of rapamycin pathway, enhanced autophagy, improved mitochondrial biogenesis and reduced anabolic signaling, all of them considered energy restriction hallmarks. Energy restriction also promotes favorable shifts in gene expression via the modulation of sirtuins (e.g., SIRT1, SIRT3), which influence chromatin remodeling, DNA repair, and metabolic regulation. [25]. Furthermore, energy restriction reshapes the gut microbiome, with significant impact on overall systemic health [26]. These adaptations consistently improve cellular, molecular, metabolic, and physiological homeostasis, altogether slowing the pace of aging and protecting against the appearance and severity of chronic diseases [22]. Among intermittent energy restriction strategies, time-restricted feeding (TRF) constitutes one of the most widely adopted approaches and exhibits the highest short-to medium-term adherence [27]. TRF restricts food intake to specific hours of the day, without necessarily altering total energy consumption. Despite this apparent simplicity, TRF-associated metabolic outcomes are influenced by several key variables including the circadian alignment of the TRF period [28,29]. Of note, important determinants of TRF efficacy remain unresolved, such as the optimal duration of the eating window [28] and/or the quality and nutritional density of food consumed [27]. Moreover, although daily TRF has been extensively investigated, it remains unclear whether intermittent TRF (iTRF) schedules can reproduce the therapeutic benefits of daily TRF (dTRF), as only a limited number of studies have begun to explore iTRF effectiveness. In Drosophila, exposure to a 1:1 iTRF regimen [1 day of TRF (20 h fasting) followed by 1 day of ad libitum (AL) recovery] significantly extended lifespan and delayed age-associated functional decline in muscle and gut tissues [30]. In mice, although a 4:3 iTRF protocol [four consecutive TRF days (18 h fasting/day) followed by 3 days of AL feeding] enhanced metabolic resilience, preserved lean mass, and remodeled the skeletal muscle [31], its efficacy relative to daily TRF could not be determined due to the absence of a daily TRF control group. Finally, although a 5:2 iTRF regimen [five TRF days (9 h fasting/day) and two AL days] prevented diet-induced body weight gain and hepatic steatosis when initiated concomitantly with high-fat diet feeding [32], its therapeutic effects in pre-existing obesity remain untested. To address this gap, we performed a head-to-head comparison of daily and intermittent TRF as therapeutic interventions in mice in which chronic metabolic imbalance had already been established by prolonged high-fat, high-cholesterol and high-fructose feeding before TRF initiation. Our data demonstrate that iTRF recapitulates the beneficial effects of dTRF, with both regimens improving obesity-associated metabolic dysfunction across physiological, cellular, and molecular levels. Methods Animal model, diets and feeding schedules All experimental procedures were carried out in accordance with applicable guidelines and regulations following the European Regulations for Animal Care under the approval of the University of Cordoba and the Regional Government Research Ethics Committees (approved animal protocols number 15/05/2018/088 and 08/03/2022/033). Four-weeks-old littermate C57BL/6 male mice were obtained from Charles River Laboratories (Charles River Laboratories, France) and housed under standard conditions for 4 additional weeks until the dietary intervention was initiated as described below. Housing conditions, with sterile filter-capped cages under controlled temperature (22–24 °C) and a modified light–dark cycle (10 h dark/14 h light) remained unchanged throughout the study. To establish a diet induced model of metabolic imbalances, 8 weeks-old C57BL/6 male mice (n = 100) were fed ad libitum with a high fat diet with added cholesterol (5.1 kcal/g, 60% kcal fat + 2% cholesterol, D12120101, Research Diets Inc, New Brunswick, NJ, USA) and 10% fructose in drinking water (F0127-5 KG, Merck KGaA, Germany) for 23 weeks (HFCF). Among them, 8 mice did not gain weight and were thus excluded from study. Thereafter, animals were divided into 5 experimental groups depending on the diet and/or the TRF pattern implemented (illustrated in Figure 1A). 1) HFCF group (n = 19), wherein mice were maintained ad libitum to the HFCF diet for the duration of the study; 2) daily TRF regimen (dTRF, n = 18), wherein mice were subjected to a daily TRF regimen, consisting of ad libitum access to the HFCF diet for 8 h during the dark phase, followed by 16 h of fasting per day with only access to water; 3) intermittent 2:1 TR F regimen (iTRF 2:1, n = 18), wherein mice were subjected to repeated cycles of 2 consecutive days of TRF followed by 1 complete day of ad libitum HFCF; 4) intermittent 5:2 TR F regimen (iTRF 5:2, n = 19), wherein mice were subjected to repeated cycles of 5 consecutive days of TRF followed by 2 complete days of ad libitum HFCF. Of note, dTRF corresponds to 30 TR F days per month, whereas both iTRF 2:1 and iTRF 5:2 correspond to approximately 20 TR F days per month, representing a ∼33% reduction in TRF days compared with daily TRF. 5) SD group (n = 18), wherein mice were switched to a standard chow diet (3.7 kcal/g, 3.5% kcal fat, LASQCdiet Rod14-R, Altromin Spezialfutter GmbH & COoKG, Germany). Mice were weighed biweekly during the establishment of metabolic imbalance (from week 0 to week 23) and weekly during the TRF intervention, during which food intake was recorded daily. - Intermittent TRF and daily TRF equally improved physiological health. A) Mouse models experimental design (left panel), and Light/dark cycles and TRF dietary regime during intervention weeks (right panel). B) Body weight evolution during diet induced chronic metabolic imbalance and after iTRF intervention starting at week 23 (dotted line, left panel) and final body weight (week 37, right panel). C) Cumulative calorie intake per mouse over the entire intervention. D-F) Whole body composition shift after TRF intervention, from week 23 till the end of the study [fat mass percentage (D), lean mass percentage (E) and lean to fat mass ratio (F). G) sum of the different fat deposits collected (vWAT, sWAT and BAT – visceral, subcutaneous and brown adipose tissue respectively). H) Latency time to fall from a rotarod or cage-top, both adjusted by body weight, and holding impulse of cage-top (Newton∗s) of each intervention compared to G1 set at 100% (dotted line). I-J) Correlations between whole body lean mass percentage and time to fall from a rotarod (I) or cage-top (J). K-L) Correlations between whole body fat mass percentage and time to fall from a rotarod (K) or cage-top (L). Data are presented as the mean ± SEM. One-way ANOVA tests followed by Tukey's multiple comparation test were implemented to compare data from B, C and G, or Kruskal-Walli's test followed by Dunn's multiple comparation test for panels D, E and F if one or more groups did not follow normal distribution assessed by Shapiro–Wilk test. On panel H a t-test or Mann Whitney test (if one or more groups did not follow normal distribution) comparing each group with HFCF group (set at 100%, dotted line). I-L linear regression with Spearman correlation value (r) and p-value. On B-G, columns that do not share a common letter (a, b, c) are statistically different (p < 0.05). On H, asterisks indicate significant difference (∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001). At the end of the study, animals were sacrificed by decapitation without anesthesia immediately before the initiation of the dark phase, when TRF mice had completed 16 h of fasting, and SD and HFCF mice had completed 14 h of light/inactive phase, a period of low spontaneous feeding activity, although food access was maintained (Supplemental Fig. 1A). Trunk blood was collected in EDTA-containing tubes (BD 363706, Franklin Lakes, NJ, USA) and kept in ice until further centrifugation to obtain plasma. Tissues were immediately excised, weighted and snap-frozen in liquid nitrogen. Plasma and tissues were stored at −20 °C or −80 °C, respectively, until posterior analysis. Additionally, a liver sections were formalin-fixed and paraffin-embedded for histological analysis. Whole body composition (nuclear magnetic resonance) and indirect calorimetry Total fat and lean mass were assessed using a Body Composition Analyzer E26-240-RMT (EchoMRI LLC, Houston, TX, USA) at the beginning of the study, after metabolic imbalances establishment, and after TRF intervention. Additionally, whole-body metabolic rate was determined by indirect calorimetry after TRF intervention (before sacrifice), as well as spontaneous activity, using the PHYSIOCAGE system (Harvard, Holliston, MA, USA) and METABOLISM analysis software (Panlab Harvard Apparatus, Barcelona, Spain). Mice were single housed in the metabolic chambers and acclimated to the environment for 48 h prior to data collection. Over five consecutive days, respiratory gases were continuously monitored to quantify oxygen consumption and carbon dioxide production, using the last 3 days for analysis. Gas sampling was performed multiplexed across chambers, utilizing a 2-minute recording interval per cage every 24 min. The resulting respiratory data were used to calculate the Respiratory Exchange Ratio (RER). Physical performance tests Physical performance was measured by cage-top (wire hang test) and rotarod (to evaluate motor coordination and balance) after TRF intervention (week 32). Mice underwent a habituation test 3 days prior to the actual test, during which they were placed on the rotarod (LE8505 Panlab) for 1 min at a constant speed (4 rpm). The results represent the average of three rounds per mouse, where the latency time to fall from a rotarod, that accelerated from 4 to 40 rpm over a 5-minute period was measured. Each round had a maximum duration of 5 min, with 15 min resting period between each round. The cage-top test consisted in suspending the animal in an inverted position from wire cage hoppers, positioned one meter above a cushioned surface. Mice were granted the liberty to grip with all four paws and move freely within the hopper, with delicate manual adjustments applied to deter tail entanglement around the wire. Then, we measured the time between the moment of inversion and when animals released the cage hoppers, to calculate the average latency to fall. Between three consecutive rounds, mice were given a 30-minute rest period. The holding impulse was calculated as previously described [33]. Glucose and insulin tolerance tests The response to glucose or insulin overload was performed after iTRF intervention (week 33). As previously reported [34], glucose tolerance test (GTT; glucose solution 1 g/kg body weight, intraperitoneal injection) was carried out before the initiation of the dark phase, after 16 h of food removal for all groups. Insulin tolerance test (ITT; insulin solution 0.75 U/kg Novolin, intraperitoneal injection) was performed before the initiation of the dark phase. At this point, TRF groups had undergone 16 h of food removal, whereas SD and HFCF control mice had experienced 12 h of the light phase followed by 2 h of food removal. During GTT and ITT, blood glucose levels were accessed by tail vein sampling at 0-, 15-, 30-, 60-, and 120-min, after glucose or insulin injection, using a standard glucometer (GlucoMen areo 2 K; A. Menarini Diagnostics, Firenze, Italia). Plasma glucose, insulin, leptin and alanine aminotransferase quantification Fasting glucose was measured after 14 h food removal in tail vein blood sampling at the beginning of the study, after metabolic imbalances establishment, and after iTRF intervention (GlucoMen areo 2 K). Plasma fasting insulin (EZRMI-13 K, EDM Millipore, St. Louis, MO, USA) and leptin (EZML-82 K, EDM Millipore) were measured in a tail vein blood sample after 14 h food removal, one week before killing the animal. Finally, alanine aminotransferase plasma levels (ALT, A7526-150, Pointe Scientific, Canton, MI, USA) were measured from trunk blood samples at the end of the study. All assays were used following manufacturer's instructions. Further details regarding the protocol, specificity, detectability, and reproducibility for each assay can be accessed at the manufacturer's websites. Liver triglycerides quantification Frozen livers samples were weighed (30–35 mg) and transferred into microtubes and lysed in 0.3 mL of chloroform/methanol (2:1 vol/vol) at 25 Hz/2 min (Tissuelyser II, Qiagen). Then, the lysates were homogenized for 3 h at 38rpm rotation, and supernatants were acquired. Afterwards, 0.09 mL of MiliQ Water was added in each tube. Samples were then centrifuged at 13,300 rpm for 20 min at Room temperature and the organic fraction was acquired and dissolved in 0.3 mL of chloroform. Triglycerides were measured with a quantitative-Colorimetric Triglyceride Determination Kit (GPO-POD, 1,001,314, Spinreact) following manufacturer's protocol. Briefly, 15 μL of sample and 135 μL of the specific reagent was dispensed into a 96-well plate and incubated for 5 min at 37 °C, followed by absorbance measurement at 505 nm. Isolation of mitochondria-enriched fractions Liver tissue samples were homogenized using a steel ball mill (MM400, Retsch, Germany) for 2 min at 25 strokes/s with pre-chilled adaptors in an isolation buffer composed of 20 mM Tris–HCl pH 7.6, 40 mM KCl, 0.2 M sucrose, 1 mM PMSF, 10 mM EDTA, 1 mM DTT, 20 μg/μL CLAP, and phosphatase inhibitor cocktails 2 and 3 (Sigma–Aldrich) diluted at 1/100. The homogenates were centrifuged at 420×g for 10 min to remove debris and cell nuclei, and the supernatants were collected. Supernatants were then centrifuged again at 6,700×g for 10 min to pellet a mitochondria-enriched fraction. These pellets were resuspended in 100 μl of isolation buffer and stored at −80 °C for subsequent analysis. Total protein content in both the RIPA extracts and the mitochondria-enriched fractions was determined using the modified Bradford dye-binding method developed by Stoscheck [35]. Immunoblotting gel electrophoresis and western blotting For Western Blot analysis, 20–30 μg of total protein were mixed with Laemmli buffer, boiled and separated on 10% acrylamide gels, and electrophoretically transferred to Hybond-ECL nitrocellulose membranes. Blots were blocked with 5% nonfat dry milk (w/v) in Tris-buffered saline containing 0.1% Tween-20 (TBS-T), then incubated overnight at 4 °C with primary antibodies, prepared in TBS-T with 5% nonfat dry milk, against SIRT3, HSP10, LC3A/B, VDAC, OxPhos cocktail for the mitochondrial complexes quantification, ATF6, and with OxyBlot protein oxidation detection (see Supplementary Table 1 for antibodies dilutions and catalog numbers). The next day, membranes were incubated for 1 h with HRP-conjugated secondary antibodies prepared in 5% nonfat dry milk in TBS-T. After washing, blots were developed using Clarity Western ECL substrate (1,705,060; Bio-Rad, Hercules, CA, USA) for 5 min. Chemiluminescent signals were captured using the ChemiDoc Imaging System (Bio-Rad) and analyzed with Biorad Image Lab 6 software. Analysis of oxidative markers Protein carbonyl levels were determined by 2,4-dinitrophenylhydrazine (DNPH) derivatization. Briefly, two aliquots of 20 μg of protein were prepared; one was used as a negative control, and the other one was treated with DNPH using an OxyBlot kit (Millipore, Billerica, MA). Proteins were separated by immunoblotting as indicated above, and the derivatized products were then detected using an anti DNP antibody, as described by the manufacturer. Respirometry analysis with isolated mitochondria The rate of oxygen consumption by mitochondria was assessed by respirometry measurements in a SeaHorse XFe24 flux analyzer (Agilent, Santa Clara, CA, USA) using mitochondrial fractions isolated from previously frozen tissue [36,37]. The analysis included the determination of maximal respiration involving complexes II + III + IV, as well as complex IV-linked maximal respiration, with 5 μg of protein per assay. Isolated mitochondria were resuspended in 50 μl of MAS buffer (70 mM sucrose, 220 mM mannitol, 5 mM KH2PO4, 5 mM MgCl2, 1 mM EGTA, 2 mM HEPES, pH 7.4), placed in 24-well SeaHorse plates, and then centrifuged at 4 °C and 3200×g for 20 min in a plate centrifuge (Eppendorf 5810 R, Hamburg, Germany) to sediment the mitochondria. Subsequently, 450 μl of MAS buffer were carefully added to each well. Assessment of maximal respiration involving complexes II + III + IV was based on the oxygen consumption rate that was stimulated by the addition of succinate in the presence of rotenone and then inhibited by antimycin A (final concentrations: 0.65 mM succinate, 0.26 μM rotenone, 0.46 μM antimycin A). Maximal respiration linked to Complex IV alone was determined from the rate of oxygen consumption stimulated by the addition of N,N,N′,N′-tetramethyl-p-phenylenediamine (TMPD) plus ascorbic acid and then inhibited by sodium azide (final concentrations: mixture of 0.5 mM TMPD and 2 mM ascorbic adjusted pH to 7.2 with KOH, 4.6 mM azide [38]. Liver RNA extraction, reverse transcription and dynamic qPCR array based on microfluidic technology for genes expression analysis RNA extraction and Dynamic qPCR were performed as previously reported by our group [[39], [40], [41]]. In summary, total RNA from liver samples was extracted with TRIzol-Reagent (Thermo-Fisher Scientific, Waltham, MA, USA) following the manufacturer instruction. Then, total RNA concentration and purity were assessed with the Nanodrop-One Microvolume UV–Vis Spectrophotometer (Thermo-Fisher Scientific) prior to retrotranscription. After DNAse treatment (RQ1 RNAse-Free DNAse, #M6101, Promega, Madison, WI, USA), 1 μg of total RNA, was retrotranscribed using a Reverse-Transcription Kit (iScript™ Advanced cDNA Synthesis Kit, 100 × 20 μl rxns #1725038, Biorad)). A qPCR dynamic array based on microfluidic technology (Standard BioTools, #BMK-M-96.96) was implemented to determine the expression levels of key genes belonging to Fatty acid metabolism (43 genes). The specific primers for all mouse transcripts used in this study were specifically designed with the Primer3-software [42,43] and are available at Supplementary Table 2. Liver mRNA expression was normalized using a normalization factor calculated with the expression levels of Actb, Ppia and Hprt using GeNorm 3.3 software, as previously reported [44]. Histopathology and morphology analysis 4% Formalin-fixed paraffin-embedded sections of liver were deparaffinized and stained with hematoxylin and eosin (H&E). Nuclei were counterstained with hematoxylin. Tissues were coded at time of collection to ensure an un-biased analysis; at least 3 images were acquired per tissue section (Bright Field Microscope DM1000, Leica, Wetzlar and ZEISS Axio Lab A1. Carl Zeiss Microscopy GmbH, Jena). Histological scores comprised three histological features, characteristic of MASLD: steatosis (0–3), lobular inflammation (0–3) and hepatocellular ballooning (0–3) performed by two blinded researchers and validated by an experienced pathologist [45]. Liver spatial lipidomics Liver lipids spatial profiling was performed at the IMIBIC Mass Spectrometry and Molecular Imaging Unit, using MALDI mass spectrometry (MS-Imaging). Briefly, fresh tissue slices were obtained by cutting the samples to a thickness of 10 μm using a cryostat, placed on conductive indium-tin oxide (ITO) slides (Intellislides, Bruker, Germany) and frozen at −80 °C until use. Then, slides were vacuum-dried for 45 min before sample conditioning. An optimized sample preparation protocol for ITO slides was applied to ensure proper sample handling. Thus, dried samples were submerged in a series of baths containing 100 mM ammonium formate in deionized water to remove sodium and potassium adducts. Subsequently, the slides were vacuum-dried again for 45 min. Then, the matrix was applied over the tissue surface using a solution of norharmane (N6252, Sigma Aldrich, Steinheim, Germany) at 7 mg/mL in chloroform: methanol 66:33% solution. The matrix solution was sprayed in 10 layers at 85 °C with a flow rate of 0.050 mL/min using an HTX TM-Sprayer™ (HTX Technologies, USA). After matrix application, slides were vacuum-dried for 40 min before mass spectrometry acquisition. Spectral acquisition was performed in positive mode using the timsTOF-FleX hybrid mass spectrometer (Bruker, Germany) along with associated software, including timsControl and FlexImaging (Bruker, Germany). Methods, voltages, laser power parameters, number of shots, pixel size (20 μm), calibration, and other settings were adjusted based on the analytical requirements of the analyses. Z-score calculations To analyze overall alterations considering several variables, a metabolic, energy restriction and lipid clusters z-scores were calculated considering different variables. For each variable, z-score was calculated by the difference between a data point and the average of the dataset, then dividing that difference by the standard deviation. Then, z-scores of each variable were summed to generate an overall z-score [46]. Specifically, the following variables for the different z-scores were included: 1) Metabolic z-score: Final body weight, adipose tissue depots [visceral (vWAT), subcutaneous (sWAT) and brown adipose tissue (BAT)], body fat and lean mass percentages, lean-to-fat ratio, fasting leptin and fasting insulin, HOMA-IR (Homeostatic Measure of Insulin Resistance) and QUICKI (Quantitative Insulin Sensitivity Check) indexes; 2) ER z-score included: liver weight, plasma ALT, western blot quantification of mitochondrial complexes I, II, III, IV, and V, VDAC, SIRT3, HSP10, LC3A/B and oxyblot, and mitochondrial maximal respiratory capacity measure by SeaHorse involving complexes II + III + IV and complex IV alone; 3) lipid clusters z-score included the 25 lipids represented on Figure 5B, used to generate the 3 lipid clusters. - iTRF interventions and dTRF promoted similar lipid profile modulation in liver. A) Partial Least Squares Discriminant Analysis (PLS-DA) of the 291 identified lipids B) Heatmap of the 25 lipids significantly altered in at least one TRF condition vs HFCF (set at 100%), grouped in clusters according to its directionality. C) Lipid z-score calculated by the sum of z-scores of the 25 lipides defining clusters A, B and C from panel B. D) Correlations of a subset of 5 upregulated and 5 downregulated lipids, compared to HFCF, with relevant metabolic parameters. E) Mass spectrometry imaging (MSI) visualization of differential lipid abundance in liver tissue sections. (Left) Spatial mapping of hepatic lipid species significantly upregulated relative to the control group (G1). (Right) Spatial mapping of hepatic lipid species significantly downregulated relative to G1. Rows represent individual experimental, with multiple liver lobe replicates shown per row. The color intensity scale reflects relative lipid ion abundance, where bright cyan denotes maximum structural lipid intensity/accumulation and dark blue/black denotes minimal detection or suppression. F) Lipids subcellular distribution assessed using LipidSig 2.0 database G) Liver Western Blot protein quantification of ATF6 (% to HFCF). Data are presented as PLS-DA components score (A), as heatmap of the means (B), mean ± SEM (C, G), Pearson correlation value heatmap (E) or heatmap of cellular components lipid composition enrichment score (F). One-way ANOVA tests followed by Tukey's multiple comparation test were implemented to compare data from panel C. On panel A and G, a t-test or Mann Whitney test (if one or more groups did not follow normal distribution) comparing each group with HFHC group set at 100%. On panel B, E and F, statistical significance was considered and represented as white circles when p-value <0.05, while p < 0.1 was indicated as a trend (t). On panel C, columns that do not share a common letter (a, b, c) are statistically different (p < 0.05). On panel G, asterisk indicates significant difference (∗p < 0.05). Of note, when z-score of HFCF resulted to be higher than SD group, the signal of z-score of the variable was inverted to negative, considering positive z-score as a positive effect of the interventions [e.g. a decrease in body weight (HFCF z-score >SD, converted to –HFCF z-score